Xofigo (radium Ra 223 dichloride) is a radiopharmaceutical used to treat prostate cancer that’s spread (metastasized) only to the bones and is causing symptoms like pain or fractures. It’s given as a quick injection through the vein at treatment centers with staff trained to safely handle medications containing radiation. After each Xofigo (radium Ra 223 dichloride) injection, it's important to handle your bodily waste (e.g., urine, feces, vomit) with care for one week to reduce the risk of exposing others to radiation. Common side effects are low blood cell counts, nausea, and diarrhea.
Xofigo (radium Ra 223 dichloride) is a radiopharmaceutical. It’s made of the radioactive chemical radium-223. Radium-223 acts like calcium in the body and is taken into the bones.
Advanced prostate cancer can sometimes spread to the bones. So when Xofigo (radium Ra 223 dichloride) is absorbed into the bone, the radioactivity damages the tumor cells there, stopping them from growing and spreading.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
No. Xofigo (radium Ra 223 dichloride) is considered a radiopharmaceutical. It uses radioactivity to damage prostate cancer cells in the bones. Since it’s targeted to the prostate cancer cells that have spread into the bones, it works in a more specific way than traditional chemotherapy. Traditional chemotherapy works against all fast-growing cells in the body, not just cancer cells.
In studies, half of the people treated with Xofigo (radium Ra 223 dichloride) lived about 3 months or longer than those who received a placebo. Talk to your provider if you have questions about how well this medication can work for you.
Xofigo (radium Ra 223 dichloride) is given over 1 minute. But you’ll have to get blood tests checked before each dose. So even though the treatment itself doesn’t take long, it’s a good idea to budget a few hours for your appointment.
Yes, it can. In a study with people who had prostate cancer that spread to the bone, those who received Xofigo (radium Ra 223 dichloride) took longer to experience the first bone-related event compared to those who received a placebo.
Xofigo (radium Ra 223 dichloride) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Xofigo (radium Ra 223 dichloride) affects your bone marrow and causes your body to make fewer blood cells. Low amounts of blood cells can raise your chance of bleeding and make you more likely to get infections. Your provider will have you do blood tests before each dose to make sure the medication is safe to take. Talk to your healthcare provider right away if you suddenly have unusual bleeding or bruising, tiredness, trouble breathing, or develop a fever.
In studies, people who received Xofigo (radium Ra 223 dichloride) together with abiraterone (Zytiga) and certain steroids (e.g. prednisone or prednisolone) had a higher than expected rate of fractures and deaths. Talk with your provider about your prostate cancer treatment plan before starting Xofigo (radium Ra 223 dichloride).
Xofigo (radium Ra 223 dichloride) can harm unborn babies. Use of effective birth control, like condoms, while taking this medication and for at least 6 months after your last dose. Also, if your partner is capable of becoming pregnant, it's important for them to also use birth control while you're on this medication and for at least 6 months after your last dose to prevent pregnancy.
Your treatment team will calculate your specific dose based on your body weight. The typical dose is 55 kBq/kg given as an infusion through the vein (IV) every 4 weeks for 6 doses.
Note: kBq is a unit of radioactivity. Since this medication works by delivering radiation, the dose is described using units that measure radioactivity.
Prostate cancer that has spread to other parts of the body, in combination with a corticosteroid: